乌鸦传媒

Charles Bankhead

Charles Bankhead

Authors >

Charles Bankhead

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. His career spans more than 30 years, including a decade with Medical World News, a leading medical trade magazine of its time. He had a long and successful freelance career before joining 乌鸦传媒 in 2007. Charles graduated with honors from Texas Tech University, receiving a BA in journalism, and completed a master's degree in mass communication, with specialization in health communication, also at Texas Tech.

Connect:

email image

Latest from Charles Bankhead

AAD over a medical illustration of the layers of the skin and a melanoma

<乌鸦传媒>High Rate of Hyperhidrosis Relief With Topical Agent

Benefit for 86% of patients treated with sofpironium bromide

A space-filling model of pembrolizumab over an x-ray showing lung cancer

<乌鸦传媒>Lung Cancer Survival Continues to Rise With Immunotherapy

Twice as many patients with advanced NSCLC alive at 5 years with pembrolizumab vs chemo

AAD over a medical illustration of the layers of the skin and a melanoma

<乌鸦传媒>Rapid Improvement in Atopic Dermatitis With Topical JAK Inhibitor

Disease activity index improved as early as week 1 with delgocitinib cream

AAD over a medical illustration of the layers of the skin and a melanoma

<乌鸦传媒>Significant Improvement in Hand Eczema With Pan-JAK Inhibitor

Disease activity indicators reduced, no safety signals with gusacitinib versus placebo

AAD over a medical illustration of the layers of the skin and a melanoma

<乌鸦传媒>Big Win in Psoriasis for Dual IL-17A/17F Inhibitor

Significant differences in clearance with bimekizumab vs secukinumab at all time points

FDA APPROVED dostarlimab (Jemperli) over a computer rendering of endometrial carcinoma

<乌鸦传媒>PD-1 Inhibitor Approved for dMMR Endometrial Cancer

Dostarlimab led to 42.3% response rate in recurrent/advanced disease

AACR over a computer rendering of a tumor

<乌鸦传媒>New Anti-PD1 Drugs Boost Survival in Treated Lung Cancer

Questions about generalizability of results with China-developed therapies

FDA APPROVED sacituzumab govitecan-hziy (Trodelvy) over a photo of the product over a microscope image of urothelial cancer

<乌鸦传媒>Another Player in Advanced Bladder Cancer

Accelerated FDA approval of sacituzumab govitecan after chemo, immunotherapy

AACR over a computer rendering of a tumor

<乌鸦传媒>Another FGFR Inhibitor Active in Bile Duct Cancers

Clinical benefit rate of 82% in patients selected for FGFR2 fusions, rearrangements

A computer rendering of prostate cancer.

<乌鸦传媒>More Benefit With Taxane for Aggressive Metastatic Prostate Cancer

Higher clinical benefit rate with front-line cabazitaxel versus androgen receptor inhibitor

鈥�

70

鈥�